GlassScriptPhysician profile
James D Rowley
NPI 1053806042
$4,795.01
in general payments reported to CMS, 2019-2025
39 companies · $795 in 2025
The $795 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,308 · 2022: $937 · 2023: $829 · 2024: $926 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,550.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $862.05 | 2021-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $707.75 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $631.56 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $316.86 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $264.64 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $237.65 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $214.82 | 2021-2023 | |
| Pfizer INC. | $188.15 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.82 | 2023-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $112.64 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.99 | 2025 | Caplyta |
| Abbott Laboratories | $87.46 | 2021-2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $80.28 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.28 | 2021-2022 | |
| Dexcom, INC. | $70.35 | 2021-2024 | Dexcom G6 Transmitter |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rowley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.